Doyle Janeen Noel has filed 4 insider transactions across 1 company since June 2025.
Most recent transaction: a grant/award of 36000 shares of Janux Therapeutics, Inc. ($JANX) on January 02, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 2, 2026 | Janux Therapeutics, Inc. | $JANX | Doyle Janeen Noel | Chief Corp. & Bus. Dev. Ofcr | A | Common Stock | 36000 | $0.00 | 80,000.0000 | 62,023,685 | 81.82% | 0.06% |
| Jan. 2, 2026 | Janux Therapeutics, Inc. | $JANX | Doyle Janeen Noel | Chief Corp. & Bus. Dev. Ofcr | A | Stock option (right to buy) | 126000 | $0.00 | 126,000.0000 | 62,023,685 | 9999.99% | 0.20% |
| June 2, 2025 | Janux Therapeutics, Inc. | $JANX | Doyle Janeen Noel | Chief Corp. & Bus. Dev. Ofcr | A | Common Stock | 44000 | $0.00 | 44,000.0000 | 53,751,480 | 9999.99% | 0.08% |
| June 2, 2025 | Janux Therapeutics, Inc. | $JANX | Doyle Janeen Noel | Chief Corp. & Bus. Dev. Ofcr | A | Stock option (right to buy) | 154000 | $0.00 | 154,000.0000 | 53,751,480 | 9999.99% | 0.29% |